239 related articles for article (PubMed ID: 31654226)
1. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.
Li S; Zhao H; Mao X; Fan Y; Liang X; Wang R; Xiao L; Wang J; Liu Q; Zhao G
Pharm Res; 2019 Oct; 36(12):168. PubMed ID: 31654226
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and in vitro antitumor activity of a transferrin receptor-targeted peptide-doxorubicin conjugate.
Li S; Zhao H; Fan Y; Zhao G; Wang R; Wen F; Wang J; Wang X; Wang Y; Gao Y
Chem Biol Drug Des; 2020 Jan; 95(1):58-65. PubMed ID: 31452330
[TBL] [Abstract][Full Text] [Related]
3. New Transferrin Receptor-Targeted Peptide-Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity.
Yu J; Mao X; Yang X; Zhao G; Li S
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675578
[TBL] [Abstract][Full Text] [Related]
4. Cellular delivery of doxorubicin mediated by disulfide reduction of a peptide-dendrimer bioconjugate.
Burns KE; Delehanty JB
Int J Pharm; 2018 Jul; 545(1-2):64-73. PubMed ID: 29709616
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
6. Transferrin Conjugated pH- and Redox-Responsive Poly(Amidoamine) Dendrimer Conjugate as an Efficient Drug Delivery Carrier for Cancer Therapy.
Hu Q; Wang Y; Xu L; Chen D; Cheng L
Int J Nanomedicine; 2020; 15():2751-2764. PubMed ID: 32368053
[TBL] [Abstract][Full Text] [Related]
7. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
8. Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity.
Mozaffari S; Salehi D; Mahdipoor P; Beuttler R; Tiwari R; Aliabadi HM; Parang K
Eur J Med Chem; 2021 Dec; 226():113836. PubMed ID: 34537446
[TBL] [Abstract][Full Text] [Related]
9. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
10. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z
Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890
[TBL] [Abstract][Full Text] [Related]
11. [(WR)
Zoghebi K; Aliabadi HM; Tiwari RK; Parang K
Cells; 2022 Jan; 11(2):. PubMed ID: 35053417
[TBL] [Abstract][Full Text] [Related]
12. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
14. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
15. In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.
Wängler C; Nada D; Höfner G; Maschauer S; Wängler B; Schneider S; Schirrmacher E; Wanner KT; Schirrmacher R; Prante O
Mol Imaging Biol; 2011 Apr; 13(2):332-41. PubMed ID: 20473573
[TBL] [Abstract][Full Text] [Related]
16. Fattigation-platform nanoparticles using apo-transferrin stearic acid as a core for receptor-oriented cancer targeting.
Amin HH; Meghani NM; Park C; Nguyen VH; Tran TT; Tran PH; Lee BJ
Colloids Surf B Biointerfaces; 2017 Nov; 159():571-579. PubMed ID: 28854413
[TBL] [Abstract][Full Text] [Related]
17. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
18. Constructing transferrin receptor targeted drug delivery system by using doxorubicin hydrochloride and vanadocene dichloride.
Zhang Y; Xiang J; Liu Y; Zhang X; Tang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5982-6. PubMed ID: 21862329
[TBL] [Abstract][Full Text] [Related]
19. Coordinated pH/redox dual-sensitive and hepatoma-targeted multifunctional polymeric micelle system for stimuli-triggered doxorubicin release: Synthesis, characterization and in vitro evaluation.
Wang L; Tian B; Zhang J; Li K; Liang Y; Sun Y; Ding Y; Han J
Int J Pharm; 2016 Mar; 501(1-2):221-35. PubMed ID: 26851356
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
